Objective: Across a woman's lifetime, variations in hormone levels are known to influence mood and wellbeing. Whether absolute or changes in hormone levels over time are associated with depression among postmenopausal women remains unclear.
A ccumulating biological and epidemiological evidence supports a role for estrogens in depression. Estrogen receptors are present in the brain, and estrogen has been shown to modulate neurotransmitter turnover (for review, see Ancelin and Ritchie 1 ) and stimulates serotonergic activity through the regulation of receptor number and function, 2 all of which strongly suggest that estrogen can influence mood and well-being. These findings are further supported by in vivo animal studies, in which a sudden decrease in the brain's exposure to estrogen has been shown to disrupt neurosteroid signalling, leading to an increase in anxiety and depression. 3 The menopausal transition is a period of marked hormone instability, 4 with intense and irregular fluctuations in the levels of estrogen, which tend to decline up to postmenopause. Research suggests that this period is associated with an increased risk for new-onset depressive disorder 5 and a higher risk of depressive symptoms for at least some women. 6<8 External stresses during the menopausal transition also seem to have a more negative impact on women's mood. 9 In addition, studies have shown that women who have undergone surgical menopause and thus experience an abrupt drop in estrogen concentrations are also at a greater risk of depression. 10<12 Short-term randomized controlled trials have demonstrated the efficacy of estradiol (E 2 ) in improving the mood of depressed perimenopausal women, 13, 14 and hormone therapy (HT) during postmenopause may enhance the positive effects of antidepressants on depressed mood. 15 On the other hand, the results of observational studies and randomized controlled trials have not all been so clear, and it is possible that certain women respond better to estrogen treatment than others do. 16, 17 Despite relatively strong evidence for a link between estrogens and depression, the results of studies that have looked at differences in serum E 2 levels between depressed and nondepressed women have been inconclusive. 18Y21 In addition, most of these studies have focused on hormone levels across the reproductive years or during the menopausal transition. Whether there is an association between low estrogen concentrations and depression in postmenopausal women remains unclear, as does the involvement of other hormones in depression in later life. Recent studies also suggest that rather than the absolute levels of plasma hormones, some women are particularly vulnerable to fluctuating hormone levels. 22, 23 The objective of this study was, therefore, to determine whether absolute or changing levels of E 2 are associated with depression in a population-based sample of postmenopausal women. The influence of other hormones, namely, folliclestimulating hormone (FSH), testosterone, and sex hormoneY binding globulin (SHBG), will also be examined.
METHODS

Study participants
This article reports on post hoc analysis of data collected from the Melbourne Women's Midlife Health Project (MWMHP), a population-based study that began in 1991 and followed women through the menopausal transition. The study protocol was approved by the University of Melbourne's Human Research Ethics Committee, and the procedures were followed in accordance with the ethical standards of the National Health and Medical Research Council. Information regarding the sampling procedure used for the MWMHP has been described in detail previously. 24, 25 In brief, households were selected via random digital telephone dialing, and women who were born in Australia, currently living in Melbourne, and between 45 and 55 years of age were invited to participate. A total of 2,001 women were recruited (response rate, 71%), 26 and they provided written informed consent. Subsequent interviews revealed that 51 of these women were actually outside the age limits for inclusion (39 were too young and 26 were older than 55), whereas a further 12 women refused to provide their date of birth and 4 women were not born in Australia. Of the remaining women, those eligible were invited to participate in the longitudinal study. Almost half of the women were not eligible for inclusion in this cohort because they had not menstruated in the previous 3 months (n = 442) and a number of women were using oral contraceptives (n = 16) or HT (n = 249). Another 427 women had undergone a hysterectomy and/or bilateral ovariectomy, and 7 were excluded because they were unsure if they had undergone such an operation. Of the 779 women who met the specified eligibility criteria for the longitudinal cohort, 341 refused participation. The 438 women who agreed (response rate, 56%) reported better selfrated health and were more likely to have a tertiary education, to exercise at least once a week, to have ever had a Papanicolaou smear, and to have undergone dilatation and curettage compared with the eligible women who refused to participate. 27 
Assessment of depression
Depressive symptoms were assessed in years 11 and 13, using a shortened version of the 20-item Center for Epidemiology Studies Depression Scale (CES-D). 28 This 10-item CES-D demonstrates good predictive accuracy when compared with the full-length version and maintains high reliability. 29, 30 Women completed the short form of the CES-D individually by responding to a series of questions concerning their mood over the last week. The scores on all questions were summed to give a maximum of 30, with higher scores indicative of depressive symptoms. A cutoff of 10 was used to identify women with signs of clinical depression. 29, 30 
Serum hormone measurements
A fasting morning blood sample was taken from all postmenopausal women at the time of interview. Plasma blood samples were collected in EDTA sample tubes, which were then centrifuged, and the plasma was stored at j20-C within half an hour of collection. Samples were then transferred and stored for up to 1 2 years at j80-C. All hormones were measured in year 11; however, only the levels of E 2 and FSH were assessed in year 13. A double antibody radioimmunoassay kit from Diagnostic Products Corporation (Los Angeles, CA) was used to measure total serum E 2 levels. In a number of cases (39.1% of women in year 11 and 51.5% in year 13), the levels of E 2 could not be determined because they were below the assay's sensitivity level. In this instance, the women were assigned the minimal detectable value of 20 pmol/L. The interassay coefficient of variation was 6.6% at 400 pmol/L and the between-assay coefficient of variation was 11% at 110 pmol/L and 13% at 470 pmol/L. FSH was measured using the TOSOH AIA1200 automated enzyme immunoassay (Abbott Laboratories), and total serum testosterone was measured using an automated, chemiluminescent enzyme immunoassay (ACS180 from Chiron), which has a minimal detection of 0.3 nmol/L. The between-assay coefficient of variation at a testosterone level of 2 nmol/L was 12%. SHBG was measured by an automated chemiluminescent enzyme immunoassay using an Immulite Automated Analyser (Diagnostic Products Corporation, Los Angeles, CA). The coefficient of variation for SHBG was 7.9% at 82.4 nmol/L. Because the levels of bioavailable E 2 and testosterone were not directly measured, the free E 2 and free androgen index (FAI) were calculated as the ratio of the measured E 2 or testosterone, respectively, to the quantity of measured SHBG, multiplied by 100. 18 The changes in E 2 and FSH levels were determined by calculating the difference in measures over the 2-year follow-up period. Only the SHBG and FAI measures could be normalized using a log transformation, and the distribution of FSH levels on the original scale was approximately normal. The absolute values of the other hormones, as well as the changes in E 2 and FSH levels, were treated uniquely as binary variables, with categories defined using the median value due to the relatively small sample size.
Other measures
As part of the questionnaires that were administered at each follow-up interview, information on sociodemographic and lifestyle characteristics, aging-related problems, and overall health was obtained. The age of the women was recorded, as well as their level of education, their living status, and current employment. They were questioned on their consumption of alcohol over the last week and whether they were current or past smokers. Body mass index (BMI; kg/m 2 ) was calculated from height and weight measurements, and women indicated their level of current physical activity.
Chronic health conditions were identified based on physical measurements and self-reporting. This included high cholesterol levels (total cholesterol, high-density lipoprotein, and low-density lipoprotein), diabetes, hypertension, chronic asthma, heart disease, stomach or bowel ulcers, arthritis, rheumatism, cancer, or migraine or use of medications for such conditions. A dichotomous variable was created to indicate whether a woman experienced at least three of these health problems, and women were also asked to evaluate their own health as Bbetter,[ Bworse,[ or Bthe same as their peers'.[ 31 From a list of 22 common symptoms, which included experiencing dizzy spells, headaches, lack of energy, skin irritations, and stiff joints, women indicated which ones bothered them in the last 2 weeks. From this checklist, women who experienced hot flushes and/or night sweats were also identified. The number and severity of hassles experienced in the last 2 weeks were identified using a shortened daily hassles scale. 32 Women's attitudes to menopause were assessed using an eight-item questionnaire in which the women noted their level of agreement to different statements about people's understanding of menopause. 9
Statistical analysis
Initial analysis compared the difference in year 11 characteristics according to depression status. Two-tailed W 2 tests and t tests were used to compare the categorical and continuous variables, respectively, between depressed and nondepressed postmenopausal women in year 13. Hormones that were associated with depressive symptoms at the 20% significance level were analyzed further in logistic regression models. The other characteristics that were associated with depressive symptoms were considered as potential confounding factors.
The odds ratios (ORs) and 95% CIs were initially calculated to determine the association between absolute or changes in hormone levels and depression status in year 13 while adjusting for year 11 depression scores (log CES-D). Multivariate logistic models were then generated with successive adjustment for a priori confounding factors: age and BMI, as well as alcohol consumption, the presence of hot flushes or night sweats, and number of years since menopause. Previous work with the MWMHP has shown that E 2 , FSH, and testosterone levels vary with age, and BMI is also associated with hormone levels. 27, 33, 34 Hot flushes are significantly associated with declining E 2 levels and increasing FSH levels, 4, 35, 36 and the levels of these hormones change depending on the number of years since menopause. 37 In addition, hormone levels have also been shown to vary with alcohol intake. 38 At the same time, these factors have all been linked to depression. Adjustment was also made for other covariates that were identified as potential confounders in the association between depressive symptoms and hormone levels from the t tests and W 2 analysis.
Secondary analysis was also undertaken to determine whether hormone levels were associated with new or incident cases of depression (CES-D Q10) in year 13. Rather than adjusting for year 11 CES-D score, this analysis excluded the 27 women with depressive symptoms in year 11. SAS version 9.1 (SAS Institute, Inc, Cary, NC) was used for the statistical analysis with a significance level of P G 0.05.
RESULTS
Study population
Of the women in the initial MWMHP longitudinal cohort, 291 participants remained after 13 years of follow-up, giving a retention rate of 67% ( Fig. 1 ). Most women who were lost to follow-up had refused further participation in the study, and the most common reason given was that they were Btoo busy with other things.[ In comparison with the women who dropped out of the study, those who remained until year 13 were better educated (W 2 1 = 31.9, P G 0.001), had less negative attitudes toward menopause (W 2 1 = 51.1, P G 0.001), had better self-rated health (W 2 1 = 31.9, P G 0.001), and were more likely to undertake physical activities (W 2 1 = 6.7, P = 0.01). However, they were also more likely to be either overweight or obese (W 2 2 = 16.9, P = 0.002) and to drink larger quantities of alcohol (W 2 1 = 18.5, P G 0.001). For the present analysis, women who had bled within the last 12 months and were thus not postmenopausal were excluded (n = 19), 39 as were current users of HT (n = 49), women who were not assessed for depressive symptoms in year 11 or 13 (n = 21), and women who did not provide blood samples for hormone measurements in both years (n = 64). This analysis is therefore based on a subsample of 138 postmenopausal women. In a number of respects, these women were significantly different from the women who were selectively excluded from this analysis. Compared with the analyzed sample, women not included in this analysis were more likely to have a lower educational level (W 2 1 = 45.1, P G 0.001), to be current smokers (W 2 1 = 8.1, P = 0.005), to have poorer self-rated health (W 2 1 = 29.1, P G 0.001), and to have more negative attitudes toward menopause (W 2 1 = 72.2, P G 0.001). The participants in this analysis, however, were more likely to consume larger quantities of alcohol (W 2 1 = 16.7, P G 0.001), to have no daily physical activity (W 2 1 = 10.4, P = 0.001), to experience bothersome physical symptoms (W 2 1 = 14.5, P G 0.001) and daily hassles (W 2 1 = 8.3, P = 0.004), and to be either overweight or obese (W 2 1 = 18.6, P G 0.001). There were no significant differences in depression status, hormone levels, or the other variables between women included in this analysis and those who were not. 
Participant's characteristics
In year 11 of the study, the mean age of the women was 60.1 years, ranging from 55.9 to 66.8 years. Less than half of these women had a tertiary education, and there were few current smokers. Most women participated in regular physical activity, and more than a third claimed that they were in good health. After the 2-year follow-up period, the prevalence of depressive symptoms among these women was 25%. The year 11 sociodemographic, health, and lifestyle characteristics of these women are summarized in Table 1 . Women with depressive symptoms were significantly more likely to be younger or closer to menopause and were less likely to have participated in regular physical activity. They also differed in respect to other health-related factors, such as their experience of hot flushes/night sweats or their number of daily hassles. These associations are in accordance with a previous analysis based on the women recruited from the MWMHP. 12 The hormone levels of the women overall and according to their depression status are shown in Table 2 . From year 11 to year 13, all women had an increase in FSH levels, with a median increase of 8.3 IU/L. In year 11, 39.1% of women had the minimal detectable levels of E 2 , and this increased to 51.5% at follow-up. Overall, 39.9% of the women had a decline in E 2 levels across the 2-year follow-up period, with a median change of 0 pmol/L. In unadjusted analysis, depressive symptoms were associated with higher levels of total E 2 in year 11, and there was a similar difference in free E 2 levels between depressed and nondepressed women, although this did not reach significance ( Table 2 ). There was a higher percentage of depressed women who experienced a decline in E 2 levels over the 2-year period, and a large increase in FSH levels was significantly associated with depressive symptoms. There was no indication that the serum levels of either testosterone, FAI, or SHBG were associated with depressive symptoms at follow-up (P 9 0.20), and thus, they were not considered further in the analysis. Table 3 shows the results of the logistic regression analysis to determine whether levels of E 2 or FSH were associated with depressive symptoms over the 2-year follow-up. Initial analysis adjusting for only baseline depression score (model 1) suggested that a change in total E 2 or FSH levels was associated with the risk of depressive symptoms, and there was also a trend for an association between depression and higher E 2 levels in year 11. Logistic models were then generated taking into account the covariates that a priori could potentially confound the association between depressive symptoms and hormone levels. Successive adjustment for age and BMI (model 2) and then with further inclusion of high alcohol consumption, number of years since menopause, and hot flushes or night sweats (model 3) did not have a substantial effect on the results.
Hormone levels and depressive symptoms in year 13
After this multivariate adjustment, a 2-year decline in E 2 levels remained the strongest risk factor for depressive symptoms. Women whose E 2 levels dropped between years 11 and 13 had a 3.5-fold increased risk of having depressive symptoms in year 13. Likewise, changes in FSH levels also seemed to be associated with depression. The results suggest that women whose FSH levels increased by 9 IU/L had more than two times the risk of depressive symptoms. The variables for the decline in E 2 or the large increase in FSH were not associated with one another (W 2 1 = 0.2, P = 0.65), and therefore, an association with one of these measures did not necessarily imply an association with the other. Using these models as a basis, adjustment was made for the other covariates that were found to be associated with depression status in year 11 at the 20% significance level ( Table 1) . After the addition of living alone, physical activity, more negative attitudes toward menopause, or a higher number of daily hassles to model 3, a decline in E 2 or a large increase in FSH levels was still significantly associated with depressive symptoms (data not shown). On the other hand, we did not find a significant association between depression and absolute levels of FSH or E 2 in year 11 or 13.
The same hormone variables were examined in the secondary analysis to determine whether absolute or changing hormone levels predicted incident cases of depression among women without depressive symptoms in year 11 (CES-D G10). Results similar to those described above were obtained (data not shown). Once again, even after multivariate analysis, a decrease in E 2 levels over the follow-up period was significantly associated with incident depression (adjusted OR, 3.80; 95% CI, 1.15-12.5; W 2 1 = 4.8, P = 0.03), and there was a trend for increased depression risk with a large increase in FSH levels (adjusted OR, 3.21; 95% CI, 0.97-10.8; W 2 1 = 3.6, P = 0.06).
DISCUSSION
The menopausal transition is a period of marked hormone instability, and the later phases of the transition are characterized by a steep increase in FSH levels, followed by a dramatic decline in E 2 levels. 40 The levels of both of these hormones are then thought to stabilize as women enter postmenopause, 41 but despite this, we have been able to demonstrate that hormone levels during the postmenopausal period may influence depression status. In particular, although we found no association between depressive symptoms and the absolute levels of E 2 or FSH, we determined that changes in the levels of these hormones were significantly associated with depressive symptoms. The risk of depressive symptoms increased more than threefold with a decline in E 2 levels over the 2-year period and, to a lesser extent, with a large increase in FSH levels. These associations were independent of other factors that are linked to both depression and hormone levels. It has been suggested that the association between E 2 levels and depressed mood, at least for perimenopausal women, could be explained by the presence of vasomotor symptoms such as hot flushes. Indeed, studies with the data collected from the MWMHP have shown that women with bothersome hot flushes were more likely to have higher negative mood scores and that hot flushes themselves were correlated with low E 2 and high FSH levels. 42 Confounding by hot flushes also explains associations between depression and E 2 that are significant only in unadjusted analysis. 43 In our analysis, however, even after adjustment for a range of variables, including age, BMI, alcohol consumption, hot flushes or night sweats, as well as various sociodemographic, health, and lifestyle factors, significant associations remained.
Absolute hormone levels and depressive symptoms
Contrary to our initial hypothesis and evidence in the literature that suggests that E 2 has a beneficial effect on , estradiol; FSH, follicle-stimulating hormone; CES-D, Center for Epidemiology Studies Depression Scale; BMI, body mass index. a Model 1 is adjusted for CES-D score (log) at baseline. b Model 2 is adjusted for CES-D score (log) at baseline, age, and BMI (G25, 25-30, and Q30 kg/m 2 ). c Model 3 is adjusted for CES-D score (log) at baseline, age, BMI (G25, 25-30, and Q30 kg/m 2 ), high alcohol consumption (eight or more drinks in the last week), years since menopause, and hot flushes or night sweats (presence vs absence). d Test statistic was compared with a W 2 distribution with 1 degree of freedom. mood, we did not find any association between absolute levels of either total or free E 2 and depressive symptoms. Most previous reports that have examined the relationship between serum hormone levels and depression have focused on the menopausal transition. In general, these studies have also failed to find an association between depression and either total plasma E 2 levels, 9,18,43<45 bioavailable E 2 levels, 18 or levels of FSH, 9, 22, 45, 46 although not consistently. Harlow et al 20 reported that women with a lifetime history of major depression had lower E 2 levels at both study enrollment and after follow-up, and positive associations between depressive symptoms and FSH have been found. 5, 20, 47 There are few studies that have examined differences in E 2 or FSH levels between depressed and nondepressed postmenopausal women. Of those who have, very small sample sizes may have limited the ability to detect significant effects in certain studies. 19, 46 In a somewhat larger study of 265 volunteers aged 70 years and older, postmenopausal women with lower E 2 levels were more likely to have depressive symptoms; however, only the results of unadjusted analysis were reported. 48 
Changes in hormone levels are associated with depressive symptoms
Our finding that the risk of depressive symptoms was associated with changes in E 2 and FSH, rather than the absolute levels of these hormones, is supported by previous research. 5, 22, 23, 49 Freeman et al 22 found that the varying hormone milieu experienced by women during the menopausal transition had an important negative effect on their mood. In fact, they found that rapidly increasing FSH levels seemed to play a more central role, with decreasing E 2 levels associated with depressive symptoms in unadjusted analysis only. Other studies of perimenopausal women, 20 however, as well as our study of postmenopause, indicate that changes in E 2 levels were a stronger risk factor than variability in FSH. During the reproductive years, there is also evidence to suggest that changes, rather than the absolute levels of reproductive hormones such as E 2 , are more important in the etiology of depression and in determining a woman's vulnerability to developing depression. 50 In addition, some have suggested that the actual rate of change of hormonal levels might also be relevant in predicting depression. 22, 51 However, the design of our study did not allow us to test this hypothesis. The negative consequences of a large change in hormone levels may help explain why surgical menopause is associated with an increased risk of depressive symptoms. 12 Previous analysis with data collected from the MWMHP did not find a significant association between E 2 or FSH levels and mood. 40 However, this analysis made use of data collected during the first 13 years of the study and thus examined changes in hormone levels across the entire menopausal transition, without excluding women who were using HT. In contrast, our current analysis focused solely on untreated postmenopausal women. In addition, because the CES-D was introduced into the MWMHP only in year 11, the previous analysis did not examine depressive symptoms as such, but instead used a measure of negative mood (negative affect scale).
Potential involvement of other steroid hormones
Testosterone has been shown to influence neurotransmitter activity, 52 and testosterone therapy can improve mood in premenopausal women with low testosterone levels. 53 Treatment with testosterone, either alone or in combination with E 2 , may also assist in the well-being of postmenopausal women. 54 In this study, however, we found that the levels of both total and bioavailable testosterone (FAI) were similar between women with depressive symptoms and those without. This finding seems relatively consistent in the literature, in the case of both perimenopausal 22,44<46,55 and postmenopausal 18, 19, 46, 55, 56 women. Likewise, we did not find any association between depressive symptoms and the levels of SHBG, a circulating hormone-binding protein, which binds estrogens and androgens and transports them to their target tissues. However, in year 13 of the study, testosterone and SHBG were not measured, and therefore, a potential association with changes in the levels of these compounds cannot be ruled out.
It is also possible that other hormones that were not measured in our study could be associated with depressive symptoms in later life, such as dehydroepiandrosterone (DHEA) and its sulfate metabolite DHEAS, which can reportedly enhance well-being. 57 Lower DHEAS levels have been reported in depressed middle-aged and older women. 18, 45, 58 On the other hand, some studies found no association between low levels of DHEA or DHEAS and depressive symptoms, 22, 44, 56 and treatment with these hormones might have no effect on mood or well-being. 59 Unfortunately, we have not yet analyzed the levels of DHEAS in years 11 or 13 of this study. Earlier work on the MWMHP, however, failed to find a significant association between DHEAS and mood. 60 Finally, most studies that have looked at estrone 18,44<46,48 or androstenedione 18, 44, 55 have reported no association with depressive symptoms.
Limitations
A limitation of the present study is the relatively small sample size such that it is possible that the negative findings result from a lack of power to detect statistical differences. In addition, because the hormones were measured only once in years 11 and 13, measurement error that results in bias toward the null hypothesis cannot be ruled out. However, despite these limitations, some significant associations were found. There are also limitations due to the floor effect with the hormone assays, in particular concerning testosterone and E 2 . Concentrations in the postmenopausal range for E 2 are around the limits of sensitivity for the assay used. More sensitive assays would allow better discrimination of differences in low hormone levels across women and, consequently, could allow better detection of associations with depressive symptoms. 61 The data collected concerning some of the covariates in this study were self-reported, which may be subject to recall bias, with depressed participants responding more negatively about their health. However, because these self-report measures concern the covariates, and because similar associations were seen in the unadjusted and adjusted analysis, it would seem that any bias did not have a substantial influence on our findings. Bias could also be introduced from the exclusion of women with missing data concerning some of the variables under analysis and those who were lost to follow-up. In particular, the women included in the current analysis had remained in the cohort for 13 years, and thus, bias may be caused by the loss of the women who had refused further participation in the study. Finally, although we attempted to control for a range of potential confounding factors that may explain the associations reported here, it is always possible that other unrecognized factors have influenced the results.
Strengths
Despite these limitations, this study has a number of strengths. The data used in this analysis come from a population-based prospective study of women recruited by random digit telephone dialing, and, therefore, the results are relevant to postmenopausal women living in the community. Depressive symptoms were assessed using an instrument that has been validated in the general population and has been judged to be a reliable tool for detecting symptoms of depressed mood in older adults. 29, 30 In addition, because detailed information was obtained for all of the participants in this study, we were able to adjust for a range of factors in the multivariate analysis, thus minimizing any confounding.
CONCLUSIONS
Our findings suggest that changes in hormone levels rather than the absolute levels are associated with depressive symptoms in postmenopausal women. In particular, a decrease in E 2 levels and, to a lesser extent, a large increase in FSH levels were associated with an increased risk of depressive symptoms over follow-up. This extends previous work with the MWMHP, 40 which indicated the importance of considering varying rather than absolute hormone levels, but these findings warrant further investigation. Larger studies of postmenopausal women are needed, with more frequent measures of hormone levels over a longer period of time. This would allow a more accurate assessment of the true effect of these hormones on depression. Our results suggest a potential role for estrogen in depression in later life and open up the possibility that modulation of E 2 levels could be used as a therapeutic tool.
